As of 2025-08-12, the Intrinsic Value of Alliance Pharma PLC (APH.L) is 16.36 GBP. This APH.L valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 64.70 GBP, the upside of Alliance Pharma PLC is -74.70%.
The range of the Intrinsic Value is 4.57 - 73.80 GBP
Based on its market price of 64.70 GBP and our intrinsic valuation, Alliance Pharma PLC (APH.L) is overvalued by 74.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 4.57 - 73.80 | 16.36 | -74.7% |
| DCF (Growth 10y) | 18.54 - 134.54 | 38.40 | -40.7% |
| DCF (EBITDA 5y) | (3.95) - 0.47 | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | 4.82 - 13.10 | 7.08 | -89.1% |
| Fair Value | -9.75 - -9.75 | -9.75 | -115.07% |
| P/E | (23.21) - (27.97) | (25.79) | -139.9% |
| EV/EBITDA | 87.91 - 138.28 | 106.14 | 64.0% |
| EPV | 83.42 - 115.24 | 99.33 | 53.5% |
| DDM - Stable | (22.24) - (103.68) | (62.96) | -197.3% |
| DDM - Multi | (2.83) - (10.29) | (4.44) | -106.9% |
| Market Cap (mil) | 355.92 |
| Beta | 0.27 |
| Outstanding shares (mil) | 5.50 |
| Enterprise Value (mil) | 419.25 |
| Market risk premium | 5.98% |
| Cost of Equity | 7.92% |
| Cost of Debt | 5.66% |
| WACC | 7.05% |